Development PipelineBrentuximab vedotin

an investigational antibody–drug conjugate directed to CD30

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

ECHELON-3: Relapsed/refractory DLBCL (BV + lenalidomide and rituximab vs lenalidomide and rituximab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

CHECKMATE 436: Relapsed non-Hodgkin lymphoma (BV + nivolumab)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

CHECKMATE 744: Relapsed/refractory second-line Hodgkin lymphoma in AYA patients (BV + nivolumab)

ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-015: Frontline Hodgkin lymphoma or PTCL in patients with significant comorbidities

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-027: Frontline early/advanced stage Hodgkin lymphoma (A+AVD with G-CSF primary prophylaxis or AN + AD)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-028: Relapsed/refractory Hodgkin lymphoma or PTCL previously treated with BV

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-032: Frontline PTCL with less than 10% CD30 expression (BV + CHP)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-033: Metastatic solid tumors after progression on PD-1 inhibitor treatment (BV + pembrolizumab)

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

SGN35-035: BV effect on CD4+ count in HIV

ClinicalTrials.Seagen.com ClinicalTrials.gov

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of brentuximab vedotin and ongoing clinical trials

Detailed information about brentuximab vedotin clinical trials

Related Videos

Brentuximab Vedotin in Combination with Nivolumab Proposed Mechanism of Action